Search results
Results from the WOW.Com Content Network
Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. [1] Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
In the UK, Hexedrone is a Class B drug under The Misuse of Drugs Act 1971 (Amendment) Order 2010 following the ACMD's report on substituted cathinone derivatives, [2] making it illegal to sell, buy, or possess without a license.
Tesofensine was also not reliably self-administered by human stimulant addicts. [ 190 ] The nocaine analog JZAD-IV-22 only partly substituted for cocaine in animals, but produced none of the psychomotor activation of cocaine, which is a trait marker for stimulant addiction.
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT).
N-Ethylhexedrone (also known as α-ethylaminocaprophenone, N-ethylnorhexedrone, hexen, and NEH) is a stimulant of the cathinone class [2] [3] that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) with IC 50 values of 0.0978 and 0.0467 μM, respectively. [4]
Oil prices bounced around quite a bit in 2024. They rallied more than 20% at one point -- topping $85 per barrel -- before cooling off toward the end of the year. Oil was recently below $70 a ...
In 2008, results demonstrating significant weight loss for tesofensine compared with placebo were published in The Lancet. The investigators concluded that tesofensine could produce at least twice the weight loss of currently approved anti-obesity drugs and should be evaluated in phase 3 trials. [3] [neutrality is disputed]
Discover the best free online games at AOL.com - Play board, card, casino, puzzle and many more online games while chatting with others in real-time.